Breaking News
Get 45% Off 0
🔎 How to spot overhyped stocks (like these) before they drop
Read more

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
5 Must-See Earnings Charts This Week By Zacks Investment Research - Nov 10, 2020

This is another busy earnings week with over 700 companies expected to report earnings. Yes, we’ve heard from FAANG and a lot of other popular, hot stocks. But there are still plenty of...

Sensata (ST) Pledges Support for EV Charging Standardization By Zacks Investment Research - Nov 10, 2020

Sensata Technologies Holding plc ST recently pledged its support for the standardization of electric vehicle (EV) charging systems by joining Charging Interface (NASDAQ:TILE) Initiative e.V....

Tech Slips Again, but Dow Adds Another 260 Points By Zacks Investment Research - Nov 10, 2020

The market calmed down quite a bit from yesterday’s exuberance as it continues to reposition after the recent blockbuster vaccine update, which hopefully signals that we're nearing the end of...

Crexendo (CXDO) Matches Q3 Earnings Estimates By Zacks Investment Research - Nov 10, 2020

Crexendo (NASDAQ:CXDO) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago. These figures are...

Transportation ETF (XTN) Hits New 52-Week High By Zacks Investment Research - Nov 10, 2020

Investors seeking momentum may have SPDR S&P Transportation (NYSE:XTN) ETF XTN on radar now. The fund recently hit a new 52-week high. Shares of XTN are up approximately 89.9% from their 52-week...

Moving Average Crossover Alert: Cadence Bancorp (CADE) By Zacks Investment Research - Nov 10, 2020

Cadence Bancorporation (NYSE:CADE) CADE is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the...

EGain (EGAN) Q1 Earnings and Revenues Beat Estimates By Zacks Investment Research - Nov 10, 2020

EGain (EGAN) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago. These figures are...

Buy Disney (DIS) Stock Before Earnings on Vaccine Hope? By Zacks Investment Research - Nov 10, 2020 1

The coronavirus has crushed some of Disney’s DIS core businesses and its parks and resorts still remain at limited capacity or closed, while its theatrical releases have come to a near halt. But...

Factors to Note Ahead of Blink Charging's (BLNK) Q3 Earnings By Zacks Investment Research - Nov 10, 2020

Blink Charging Co (NASDAQ:BLNK). BLNK is set to report third-quarter 2020 results on Nov 12.The Zacks Consensus Estimate for third-quarter loss per share has been steady at 9 cents in the past 30...

Top Stock Picks for Week of November 9, 2020 By Zacks Investment Research - Nov 10, 2020

Newmont Corporation NEM, is one of the world's largest producers of gold with several active mines in Nevada, Peru, Australia and Ghana.Adjusted earnings beat the Zacks Consensus Estimate. Newmont's...

ETFs Riding the Latest Coronavirus Vaccine Optimism Wave By Zacks Investment Research - Nov 10, 2020

The total number of coronavirus cases has crossed the grim mark of 50 million. Notably, the world’s largest economy has seen more than 10 million cases alone. The worsening coronavirus crisis is...

Leveraged ETF Areas That Gained the Most on Vaccine Hopes By Zacks Investment Research - Nov 10, 2020

Wall Street spiked on Nov 9 on news that a Pfizer PFE and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial. The vaccine is the first to be...

Vaccine Hopes & Divided Government: Sector ETFs to Win By Zacks Investment Research - Nov 10, 2020

Wall Street has been charged up since election. Now, the Nov 9 news that a Pfizer PFE and BioNTech BNTX vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has...

Continue with Apple
Continue with Google
or
Sign up with Email